Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

Evaluate the safety profile and tolerability of topical phosphodiesterase 4 (PDE4) inhibitors versus vehicle as treatment for atopic dermatitis in published studies.A search was performed in Medline/PubMed, Web of Science, and Cochrane Library databases on September 27, 2021, by 1 evaluator, without...

Descripción completa

Detalles Bibliográficos
Autores: Martín Santiago, Ana, Puig i Sardà, Susana, Arumí, Daniel, Rebollo Laserna, Francisco José
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/201455
Acceso en línea:https://hdl.handle.net/2445/201455
Access Level:acceso abierto
Palabra clave:Dermatitis atòpica
Inhibidors de fosfodiesterases
Atopic dermatitis
Phosphodiesterase Inhibitors
id ES_d7a1c33fdfb8cfd4b4e7cfd65a05c6c2
oai_identifier_str oai:recercat.cat:2445/201455
network_acronym_str ES
network_name_str España
repository_id_str
spelling Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-AnalysisMartín Santiago, AnaPuig i Sardà, SusanaArumí, DanielRebollo Laserna, Francisco JoséDermatitis atòpicaInhibidors de fosfodiesterasesAtopic dermatitisPhosphodiesterase InhibitorsEvaluate the safety profile and tolerability of topical phosphodiesterase 4 (PDE4) inhibitors versus vehicle as treatment for atopic dermatitis in published studies.A search was performed in Medline/PubMed, Web of Science, and Cochrane Library databases on September 27, 2021, by 1 evaluator, without restrictions on publication dates or languages. Terms such as atopic dermatitis, phosphodiesterase 4 inhibitors, calcineurin inhibitors, and randomized controlled trials were included. The database searches were carried out by 1 evaluator. The titles and abstracts were reviewed for the identification and evaluation of potentially eligible studies. Study selection was made by two reviewers, so there was no intra-examiner statistic at the study selection step. The full-text articles were reviewed to determine whether or not they would be included in the systematic review. Global analyses, which included studies with both unclear and low risk of bias and subanalyses of studies with a low risk of bias were performed.Out of 237 identified articles, 14 clinical trials were included in the meta-analysis. In global analyses of studies with low and unclear risk of bias, topical treatment with PDE4 inhibitors did not differ from vehicle treatment in global treatment emergent adverse events (relative risk?=?0.99; 95% CI, 0.87-1.14; P?=?0.94) or in serious emergent adverse events appearance (relative risk?=?0.92; 95% CI, 0.39-2.20; P?=?0.86). In subanalyses of studies with a low risk of bias, a reduced rate of atopic dermatitis exacerbation was observed in PDE4 inhibitors compared with the vehicle (relative risk?=?0.62; 95% CI, 0.39-0.98; P?=?0.04) and risk of pain at the application site was confirmed (relative risk?=?2.59; 95% CI, 1.27-5.28; P?=?0.01).PDE4 inhibitors did not show differences from vehicle treatment in treatment emergent adverse events or serious emergent adverse events incidence. In studies with low risk of bias, PDE4 inhibitors had a statistically significant risk of producing pain and reduced occurrence of atopic dermatitis exacerbation.© 2022 The Author(s).Elsevier BV2023202320222023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion12 p.application/pdfhttps://hdl.handle.net/2445/201455Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1016/j.curtheres.2022.100679Current Therapeutic Research - Clinical And Experimental, 2022, vol. 96https://doi.org/10.1016/j.curtheres.2022.100679cc by-nc-nd (c) Martín Santiago, Ana et al., 2022http://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2014552026-05-29T05:05:01Z
dc.title.none.fl_str_mv Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
title Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
spellingShingle Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
Martín Santiago, Ana
Dermatitis atòpica
Inhibidors de fosfodiesterases
Atopic dermatitis
Phosphodiesterase Inhibitors
title_short Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
title_full Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
title_fullStr Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
title_full_unstemmed Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
title_sort Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
dc.creator.none.fl_str_mv Martín Santiago, Ana
Puig i Sardà, Susana
Arumí, Daniel
Rebollo Laserna, Francisco José
author Martín Santiago, Ana
author_facet Martín Santiago, Ana
Puig i Sardà, Susana
Arumí, Daniel
Rebollo Laserna, Francisco José
author_role author
author2 Puig i Sardà, Susana
Arumí, Daniel
Rebollo Laserna, Francisco José
author2_role author
author
author
dc.subject.none.fl_str_mv Dermatitis atòpica
Inhibidors de fosfodiesterases
Atopic dermatitis
Phosphodiesterase Inhibitors
topic Dermatitis atòpica
Inhibidors de fosfodiesterases
Atopic dermatitis
Phosphodiesterase Inhibitors
description Evaluate the safety profile and tolerability of topical phosphodiesterase 4 (PDE4) inhibitors versus vehicle as treatment for atopic dermatitis in published studies.A search was performed in Medline/PubMed, Web of Science, and Cochrane Library databases on September 27, 2021, by 1 evaluator, without restrictions on publication dates or languages. Terms such as atopic dermatitis, phosphodiesterase 4 inhibitors, calcineurin inhibitors, and randomized controlled trials were included. The database searches were carried out by 1 evaluator. The titles and abstracts were reviewed for the identification and evaluation of potentially eligible studies. Study selection was made by two reviewers, so there was no intra-examiner statistic at the study selection step. The full-text articles were reviewed to determine whether or not they would be included in the systematic review. Global analyses, which included studies with both unclear and low risk of bias and subanalyses of studies with a low risk of bias were performed.Out of 237 identified articles, 14 clinical trials were included in the meta-analysis. In global analyses of studies with low and unclear risk of bias, topical treatment with PDE4 inhibitors did not differ from vehicle treatment in global treatment emergent adverse events (relative risk?=?0.99; 95% CI, 0.87-1.14; P?=?0.94) or in serious emergent adverse events appearance (relative risk?=?0.92; 95% CI, 0.39-2.20; P?=?0.86). In subanalyses of studies with a low risk of bias, a reduced rate of atopic dermatitis exacerbation was observed in PDE4 inhibitors compared with the vehicle (relative risk?=?0.62; 95% CI, 0.39-0.98; P?=?0.04) and risk of pain at the application site was confirmed (relative risk?=?2.59; 95% CI, 1.27-5.28; P?=?0.01).PDE4 inhibitors did not show differences from vehicle treatment in treatment emergent adverse events or serious emergent adverse events incidence. In studies with low risk of bias, PDE4 inhibitors had a statistically significant risk of producing pain and reduced occurrence of atopic dermatitis exacerbation.© 2022 The Author(s).
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/201455
url https://hdl.handle.net/2445/201455
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.curtheres.2022.100679
Current Therapeutic Research - Clinical And Experimental, 2022, vol. 96
https://doi.org/10.1016/j.curtheres.2022.100679
dc.rights.none.fl_str_mv cc by-nc-nd (c) Martín Santiago, Ana et al., 2022
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc-nd (c) Martín Santiago, Ana et al., 2022
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 12 p.
application/pdf
dc.publisher.none.fl_str_mv Elsevier BV
publisher.none.fl_str_mv Elsevier BV
dc.source.none.fl_str_mv Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421022878367744
score 15,812429

Similares en LA Referencia